# Open Multicenter Study for Assessment of Efficacy and Safety of Molnupiravir in Adult Patients With COVID-19

> **NCT05595824** · PHASE3 · COMPLETED · sponsor: **Promomed, LLC** · enrollment: 240 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Molnupiravir (Esperavir)
- **DRUG:** Standard of care

## Key facts

- **NCT ID:** NCT05595824
- **Lead sponsor:** Promomed, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-01
- **Primary completion:** 2022-03-11
- **Final completion:** 2022-03-11
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2022-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05595824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05595824, "Open Multicenter Study for Assessment of Efficacy and Safety of Molnupiravir in Adult Patients With COVID-19". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05595824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*